drugset / Trial / NCT07514260

A Study to Assess Adverse Events, Tolerability, and Pharmacokinetics of Subcutaneous Injections of ABBV-295 in Healthy Adult Japanese Participants With Overweight or Obesity.

NCT07514260

Phase 1 Recruiting 24 enrolled AbbVie
RandomizedParallel-groupTriple-blindBasic science

Summary

The purpose of this study is to assess the adverse events, tolerability, and Pharmacokinetics (PK) of subcutaneous injections of ABBV-295 in healthy adult Japanese participants with overweight or obesity.

Timeline

Start
2026-03-31
Primary completion
2027-01
Completion
2027-01

Drugs

EvaluationDrugModalityDoseRoute
Subject ABBV-295 Unknown Subcutaneous

Indications

No indication recorded.